# CardioPulmonary Vascular Biology COBRE

> **NIH NIH P30** · OCEAN STATE RESEARCH INSTITUTE, INC. · 2024 · $898,356

## Abstract

The vision of the CardioPulmonary Vascular Biology (CPVB) COBRE program is to develop effective approaches
to prevent and treat vascular diseases affecting the pulmonary and cardiovascular systems through better
understanding of disease mechanisms. This will be accomplished by serving as an interdisciplinary center which
promotes collaborative research and provides excellent technical support and resources to investigators. The
overall mission of the CPVB COBRE program has been to build the human and technical infrastructure and
services that serve as catalysts to increase CPVB research in the state. Cardiovascular and pulmonary diseases
are among the leading causes of morbidity and mortality in the US and in the world. Coronary artery disease
(CAD) is the leading cause of morbidity and mortality. Respiratory diseases are the 3rd and 4th leading causes
of death and are frequently complicated by pulmonary vasculopathy and cardiovascular co-morbidities that
markedly worsen prognosis. We have learned that infection with SARS-CoV-2 virus damages multiple organs,
with cardiovascular, respiratory, and vascular complications. Thus, there is an important need to understand the
pathogenesis of cardiopulmonary vascular diseases in order to develop more effective treatments and
prevention. The overall goal of the CPVB COBRE program is to facilitate high impact vascular biology research.
The CPVB COBRE program provides infrastructure with administrative, pilot project, and two technical cores,
thus providing opportunities to expand areas of investigation, experimental and technical approaches, and
scientific collaborations. The specific aims of Phase III CPVB COBRE are to: i) award high-impact research
projects in the area of cardiopulmonary vascular biology; ii) provide effective and high-quality services in cell
isolation and ex vivo organ function (CIOF), mitochondrial function, and in vivo imaging (MF-II); iii) collaborate
with IDeA programs in Rhode Island (RI) and other states to foster scientific networks by providing programming,
funding, technical services, and resources to enhance research productivity; and iv) maintain a robust line of
investigation in vascular biology that meets the needs of the scientific community and furthers research in
prevention and treatment of cardiopulmonary vascular diseases. Continuation of the CPVB COBRE into Phase
III will sustain the administrative structure for seminars and workshop planning, engagement, and professional
development support of investigators, and expertise in cell isolation and ex vivo organ function, mitochondrial
function, and in vivo imaging. We will expand and enrich the vascular biology research community by promoting
new collaborations and engaging scientists new to the field from a variety of disciplines. At the end of Phase III,
we expect to transition to a sustainable CPVB Center serving as a home to the CVPB research community with
high quality core services, significant institutional supp...

## Key facts

- **NIH application ID:** 10850885
- **Project number:** 5P30GM149398-02
- **Recipient organization:** OCEAN STATE RESEARCH INSTITUTE, INC.
- **Principal Investigator:** Gaurav Choudhary
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $898,356
- **Award type:** 5
- **Project period:** 2023-06-01 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10850885

## Citation

> US National Institutes of Health, RePORTER application 10850885, CardioPulmonary Vascular Biology COBRE (5P30GM149398-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10850885. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*